FRCP; for the PRESERVE Study Team IMPORTANCE Blood pressure (BP) lowering is considered neuroprotective in patients with cerebral small vessel disease; however, more intensive regimens may increase cerebral hypoperfusion. This study examined the effect of standard vs intensive BP treatment on cerebral perfusion in patients with severe small vessel disease. OBJECTIVE To investigate whether standard vs intensive BP lowering over 3 months causes decreased cerebral perfusion in small vessel disease.
C erebral small vessel disease (SVD) causes 20% of all ischemic strokes 1 and is the most common cause of vascular cognitive impairment. 2 It is thought that a diffuse arteriopathy of the cerebral small vessels results in hypoperfusion and impaired cerebral autoregulation, with subsequent ischemia leading to white matter hyperintensities (WMHs) visible on T2-weighted magnetic resonance imaging (MRI), as well as lacunar infarction. 2 Hypertension is the most important risk factor for SVD. 3 Prior studies have reported that more intensive blood pressure (BP) lowering (typically targeting a systolic BP of approximately 120 mm Hg compared with the standard target of 140 mm Hg) is associated with a reduction in cardiovascular events in primary prevention 4 and with decreased recurrent stroke risk in secondary prevention in unselected patients with stroke. 5 Such approaches may also be beneficial in SVD, but concern has been raised that overzealous BP lowering could exacerbate hypoperfusion, 6 extending brain injury.
Studies 7, 8 have shown reduced cerebral blood flow (CBF) in the white matter (WM) (and normal-appearing WM [NAWM]) of patients with SVD and have shown that the degree of hypoperfusion correlates with the severity of WMHs, consistent with a causal role in the disease pathogenesis. It has also been demonstrated that the limits of autoregulation are shifted upward as a consequence of structural vascular adaptation in individuals with chronic hypertension. 9 This evidence has led to the hypothesis that a higher systemic BP is required to maintain adequate CBF in SVD and that excess BP lowering may increase ischemia and worsen WMHs and cognition. 10 However, a 2013 study 11 demonstrated that intensive BP lowering in elderly patients with hypertension without stroke was associated with increased CBF, hypothetically due to a reshifting of the cerebral autoregulatory curve. In addition, a large trial on SVD showed a trend toward reduced recurrent stroke with intensive BP lowering. 12 However, many patients in that study had isolated lacunar infarction without WMHs. Whether intensive BP lowering may be associated with worse outcome in patients with severe SVD and confluent WMHs, which is the group in whom severely reduced CBF and autoregulation have been reported, remains uncertain. To address this question, we performed a randomized clinical trial to investigate if standard vs intensive BP lowering in patients with lacunar stroke and confluent WMHs has different effects on CBF over 3 months.
Methods

PRESERVE Study
The PRESERVE study is an ongoing, 2-year, multicenter, randomized clinical trial that tests standard vs intensive BP treatment regimens in patients with severe SVD on outcomes of WM disease (assessed by diffusion-tensor imaging) and cognition. This article presents a nested substudy that investigates CBF change over the first 3 months of the trial. The full protocol can be found in the Supplement.
Population
Screening by an experienced neurologist (B.M., U.K., or H.S.M.) ensured that all participants had MRI-confirmed clinical lacunar stroke, confluent WMHs graded as 2 or higher on the Fazekas Scale, 13 hypertension, and no stroke within 3 months before study commencement. Detailed inclusion and exclusion criteria have been described previously. 14 All patients gave written informed consent. The study was approved by the Harrow National Research Ethics Service committee and is registered with the UK Clinical Research Network.
A power calculation using arterial spin labeling (ASL) data 15 from elderly controls showed that the planned sample size of 60 was powered at 0.9 to detect a 24% reduction in WM CBF and a 25% reduction in gray matter (GM) CBF (P = .01). Seventy patients with hypertension were recruited at 2 English university medical centers ( 
Clinical Assessments
A neurologist or stroke physician (B.M., U.K., or other nonauthors) examined all participants. Cerebrovascular risk factors were recorded. At each participant visit (described below in the Trial Design, Randomization, and Treatment subsection), adverse events (AEs) and serious AEs (SAEs) were recorded. In addition to any general problems that had been experienced (eg, swollen ankles), participants were asked specifically about any falls or postural related dizziness that had occurred since the last visit. Any events reported were classified by likelihood of having been caused by a study drug (rated as none, remote, possible, probable, or definite) and classed as falls, postural related dizziness, or other. outcomes after trial commencement. There were no interim analyses or stopping guidelines. Treatment allocation was known to participants and clinical staff (B.M., U.K., and other nonauthors), but analysis of data was performed masked.
Assessments in clinic were performed at baseline, 4 weeks, and 12 weeks. Additional clinic or telephone checkups were performed as necessary. Participants took daily sitting readings with home BP monitors for at least 3 days before each check-up. During clinic visits, systolic and diastolic BP was measured in a sitting position 3 times after a 10-minute rest period in a quiet room. The recorded BP was the mean of the second and third measures. At each checkup, if the participant's BP was above his or her study target (and provided that hypotensive symptoms did not prevent it), an increase in antihypertensive medication was prescribed. Results presented and used in the analysis were clinic BP readings.
Treatment algorithms for standard and intensive BP lowering protocols consistent with the British Hypertension Society/National Institute for Health and Care Excellence guidance on drug treatment of hypertension were used for reference. 16 Final treatment decisions were made by the local study principal investigator (U.K. at site 1 and G.A.F. at site 2). No treatment changes were made for any participant before he or she had a baseline MRI scan.
End Points
The primary end point was change in whole-brain CBF. Secondary end points were change in GM, WM, and NAWM CBF.
MRI Protocol
Site 1 used a 3-T Achieva TX imaging system (Philips Medical Systems), while site 2 initially used a 3-T Achieva (n = 24) and then a 3-T Achieva TX (n = 5) after an upgrade (all participants received both scans on the same scanner). At baseline, the protocol included 3-dimensional (3-D) T1-weighted (T1W) and 2-dimensional fluid-attenuated inversion recovery (FLAIR) and pulsed ASL sequences. The T1W and ASL sequences were repeated at the 3-month time point. Details of each sequence are given below.
Sagittal 3-D T1W images included turbo field echo, voxel size of 1-mm isotropic, field of view (FOV) of 240 × 170 mm 3 , and repetition time/echo time of 8.27/4.61 milliseconds (site 1) and 9.81/4.60 milliseconds (site 2). Axial FLAIR included voxel size of 0.48 × 0.48 × 3 mm 3 , FOV of 230 × 230 mm 2 , 57 slices, repetition time/echo time of 11 000/120 milliseconds, and inversion time of 2800 milliseconds.
Axial pulsed ASL included FOV of 256 × 256 mm 2 , 10 slices, and inversion time at the most inferior slice of 1500 milliseconds. Site 1 used echo-planar imaging-based signal targeting by alternating radiofrequency pulses (EPISTAR), 17 withavoxel sizeof3.2×3.2×6mm 3 , repetition time/echo time of 4000/27 milliseconds, 40°flip angle, and 120 tag/control pairs. Site 2 used flow-sensitive alternating inversion recovery (FAIR), 18 wi t hav o x e ls i z eo f4×4×6m m 3 , repetition time/echo time of 2500/12.59 milliseconds, 90°flip angle, and 100 tag/control pairs. Additional images were acquired for the ASL sequences. These included M0 and Geo EPI images for EPISTAR (voxel sizeof3.2×3.2×6mm 2 , FOV of 256 × 256 mm 2 , 10 slices, 90°flip angle, 1 acquisition, and repetition time/echo time of 15 000/27 milliseconds for M0 and 500/18 milliseconds for Geo) and sets of 6 acquisitions at inversion times of 900, 1200, 1800, 2100, and 2400 milliseconds for FAIR (same acquisition as the main sequence).
To ensure standardization, 4 healthy individuals underwent the full imaging protocol at each site before study commencement. The ASL data were preprocessed using standard techniques to create flow-weighted images, the histograms of which were examined, and consistent results between sites were found.
Data Processing
ASL Preprocessing
Arterial spin labeling is an MRI technique that quantifies CBF without exogenous contrast agent. It instead uses the difference in signal between images where blood has or has not been magnetically tagged and converts this into CBF (in milliliters per minute per 100 g) via a model that takes into account variables such as the efficiency of the magnetic tag. It shows good agreement with contrast-enhanced MRI in populations with acute stroke 19 and is considered a robust method of measuring CBF. 20 The ASL image series were motion corrected using automated image registration (http://www.loni.usc.edu /Software/AIR). 21 The difference in signal between average tag and control images was calculated, creating the difference image (dm). All tag/control images were averaged to create a magnitude image (M). The proton density (M0) image was acquired differently between the 2 sequences: for EPISTAR, the M0 image acquired during scanning was used, while for FAIR it was generated by fitting of the inversion recovery curve (modeled from the additional inversion time acquisitions). The dm/M0 images were coregistered to the M image using Statistical Parametric Mapping 8 (SPM8) (http://www.fil.ion .ucl.ac.uk/spm/) "coreg." 22
Region-of-Interest Generation
The WMHs were marked on the baseline FLAIR images as previously described. 14 24 and a part of the FMRIB Software Library 25 ; for site 2, the registration was via the Geo image to improve registration success). FLAIR scans were registered to T1W images. Lesion masks and the segmented tissue probability maps (TPMs) were transformed into ASL space using these registrations (concatenated where necessary).
The transformed tissue probability maps were thresholded (at 0.5), binarized, and with the lesion masks used to create final masks of whole brain, GM, all WM, and NAWM.
After visual inspection, any voxels that were outside of the brain (as defined by the M image) were removed from the masks.
CBF Calculation
The estimated signal in M0 images caused by cerebrospinal fluid partial volume was subtracted from the images. Cerebral blood flow was then calculated 26 using MATLAB (version R2015a 8.5.0; MathWorks) (https://uk.mathworks.com/), where blood longitudinal relaxation time is 1550 milliseconds, 18 blood tissue partition coefficient is 0.98 mL/g, 27 and inversion time of the most inferior slice is 1500 milliseconds. Other variables differed between sequences. For FAIR, slice timing delay is 51 milliseconds, inversion efficiency (α) is 0.99, and transit delay (Δt) is 458 milliseconds. For EPISTAR, slice timing delay is 41 milliseconds, α is 0.9, and Δt is 877.5 milliseconds. The CBF maps were calculated for each slice (accounting for timing delay), with total CBF for each tissue being an average of CBF across slices, weighted by the volume per slice.
Statistical Analysis
Analyses were performed using SPSS (version 23; IBM Corporation). Variable distribution was measured by visual inspection and Kolmogorov-Smirnov test. Key demographic variables and risk factors were compared between treatment groups by independent t test, Mann-Whitney test, and χ 2 test as appropriate. The number of AEs whose likelihood of being caused by the study drug had been deemed as possible/probable/definite was compared between treatment groups by Mann-Whitney test. Baseline CBF values for whole brain were compared by independent t test between sites to test for any site-related differences. These analyses were conducted using all available data, while all subsequent analyses considered only participants who returned usable ASL data sets from both time points.
Systolic and diastolic BP was compared between time points by paired t tests within each treatment group. Change in systolic and diastolic BP (ie, 3-month minus baseline BP) was compared by independent t tests between treatment groups.
End Point Analyses
Analyses were performed on an intent-to-treat basis, were 2 tailed with α = .05, and controlled for site. Change in CBF (ie, 3-month minus baseline CBF) was compared between treatment groups using univariate analysis of variance (ANOVA). The Bayes factor 28 was calculated for the whole-brain CBF model as an additional means of estimating the strength of the primary end point finding.
Further secondary analyses repeated the above ANOVA models but only included intensive group participants who reached their target vs standard group participants whose 3-month systolic BP exceeded 130 mm Hg (thus controlling for participants whose final BP may undermine study assumptions). Finally, multivariable linear regression was performed comparing change in CBF (in all regions of interest [ROIs]) with change in systolic and diastolic BP.
Levine test of equal variances and inspection for normal distribution of residuals were conducted to ensure that ANOVA and regression model assumptions were met. An α value of .05 was used for all tests.
Results
The PRESERVE trial began recruitment on February 29, 2012. The last patient included was recruited on October 21, 2015. Recruitment across all PRESERVE sites closed on October 30, 2015. Patient flow is shown in Figure 1 . Sixty-two participants returned complete, usable data sets (36 at site 1 and 26 at site 2, including 33 in the standard group and 29 in the intensive group). Across this group of 62 participants, the mean age was 69.3 years, and 60% (n = 37) were male; sex distribution within treatment groups was 64% (21 of 33) in the standard group and 55% (16 of 29) in the intensive group. Characteristics of those who dropped out (n = 6) were descriptively similar to those who remained in the study. For those who dropped out, the mean age was 69.4 years, 4 of 6 were male, the mean baseline systolic BP was 152 mm Hg, and the mean baseline Montreal Cognitive Assessment (MoCA) score was 24.50. For those who stayed in the study, the mean age was 69.5 years, 61% (39 of 64) were male, the mean baseline systolic BP was 151 mm Hg, and the mean baseline MoCA was 24.72.
Demographics within treatment groups are listed in Table 1 . No variable was significantly different between groups.
Baseline whole-brain CBF did not differ between the 2 sites. The mean (SD) at site 1 was 30.7 (11.3) mL/min/100 g, and the mean (SD) at site 2 was 33.7 (10.2) mL/min/100 g (P = .25).
BP Measurements in the 2 Treatment Groups
The mean systolic/diastolic BP changed from 150/83 mm Hg at baseline to 141/79 mm Hg at 3 months in the standard group and from 154/88 mm Hg at baseline to 126/75 mm Hg at 3 months in the intensive group, achieving a between-group separation of 15 mm Hg (systolic). Therefore, the mean (SD) systolic/diastolic BP change was 8 (12)/4 (9) mm Hg in the standard group and 27 (17)/13 (13) mm Hg in the intensive group. Change in systolic and diastolic BP was significantly different between treatment groups (P < .001 for systolic and P = .002 for diastolic) and within treatment groups (standard group P = .001 for systolic and P = .02 for diastolic; intensive group P < .001 for systolic and P < .001 for diastolic). At 3 months, 13 of 33 (39%) standard group participants and 18 of 29 (62%) intensive group participants had reached their BP targets.
Change in CBF Between Treatment Groups
Cerebral blood flow values across the entire sample were 31.6 mL/min/100 g for whole brain, 45.1 mL/min/100 g for GM, 22.0 mL/min/100 g for all WM, and 22.8 mL/min/100 g for NAWM. Baseline CBF values did not differ between treatment groups in any ROI. Individual participant change in CBF by treatment group is shown in Figure 2 .
The primary end point, change in whole-brain CBF, did not differ between the 2 treatment groups: the mean (SD) change was −0.5 (9.4) mL/min/100 g in the standard group vs 0.7 (8.6) mL/min/100 g in the intensive group (partial η 2 , 0.004; 95% CI [based on estimated marginal means], −3.551 to 5.818; P = .63). The Bayes factor was 0.217 (ie, these findings were 4.61 times more likely to occur under the null hypothesis, giving moderate support for the null according to conventional interpretation. 29 There were no differences in CBF change between treatment groups for GM, all WM, or NAWM. Table 2 lists the full results.
Secondary Analyses
Further secondary analyses showed no association between change in systolic/diastolic BP and change in CBF: the systolic/diastolic P values for ROIs were .73/.88 for whole brain, .67/.87 for GM, .60/.71 for all WM, and .65/.75 for NAWM. There were no differences in CBF change when groups were restricted to standard group participants whose final systolic BP exceeded 130 mm Hg (n = 29) and intensive group participants who reached their target BP (n = 18) (P = .89 for whole brain, P = .93 for GM, P = .95 for all WM, and P = .97 for NAWM). Table 3 lists the full results.
Adverse Events
Mann-Whitney test showed no difference in the number of study drug-related AEs between the 2 groups, with a mean (SD) of 0.21 (0.65) (median, 0) for the standard group and a mean (SD) of 0.32 (0.75) (median, 0) for the intensive group (P = .44). Adverse events were 
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Effect of Standard vs Intensive Blood Pressure Control on Cerebral Blood Flow in Small Vessel Disease reported 29 times, in 17 participants (9 intensive and 8 standard), and were deemed to be related to the study drug in 17 cases, among 10 participants (6 intensive and 4 standard).
There was no difference between groups in the number of falls (1 each) or postural related dizziness (2 each). No SAEs were recorded. 
Discussion
In this randomized clinical trial, we investigated the effect of standard vs intensive BP lowering on CBF in patients with severe symptomatic SVD, as manifested by both lacunar stroke and confluent WMHs. Our results showed no difference in change in CBF (of any studied ROI) over the 3-month follow-up period between the 2 treatment groups. Furthermore, we found no excess of AEs in the intensive group, including potentially hypotension-related events. This provides support that intensive BP reduction regimens do not cause hypoperfusion in patients with severe symptomatic SVD.
Intensive BP lowering has been shown to reduce cardiovascular end points in patients without previous cardiovascular disease. 4 However, there is concern that it may be hazardous in patients with extensive SVD, in whom reduced CBF and impaired cerebral autoregulation have been previously demonstrated. 10 Therefore, our results are reassuring that intensive treatment can be used in this patient cohort.
These findings complement the Secondary Prevention of Small Subcortical Strokes 3 trial, 12 which did not measure CBF but applied a similar BP regimen to patients with MRI-confirmed lacunar stroke (but not necessarily confluent WMHs). The intensive treatment was tolerated compared with the standard treatment with regard to outcomes such as SAEs and also showed a trend toward a reduced stroke rate. However, our findings do not support previous work in patients with hypertension without stroke or SVD, 11 which found that intensive treatment raised CBF via resetting of the cerebral autoregulatory curve. This may be due to patients with SVD having more severe cerebrovascular disease than the elderly participants with hypertension included in that study, meaning that a potential increase either may not be possible because of the extent of their preexisting damage or may take longer to achieve.
The PRESERVE study will investigate this last point when the 2-year study is completed.
Limitations
Our study has limitations. The ASL sequences differed slightly; however, baseline CBF values were not significantly different between sites. Because randomization was stratified across sites, this should not have influenced any analyses. The year the study was planned (2010-2011) also restricted ASL techniques; as such (and to maintain data consistency throughout the study duration), recent advances such as QUIPSS (quantitative imaging of perfusion using a single subtraction) were not used. The lack of a FLAIR scan at the 3-month time point means that new WMHs would be classified as NAWM at follow-up (but NAWM findings did not differ from other ROIs, so this is unlikely to have affected any interpretation). Although we achieved our target treatment group BP difference of 15 mm Hg (systolic), only 62% (18 of 29) of intensive group participants reached their target. This diminishes power for the primary and secondary ANOVAs (by data noise and low numbers, respectively). While the regression analysis (which would be unaffected by this) also supports our conclusion of no connection between BP and CBF change, these considerations, as well as the Bayes factor showing moderate support for the null hypothesis, mean that interpretation should be approached with a degree of caution. Finally, because patients who had a stroke within 3 months were ineligible for the study, our findings are not applicable to acute poststroke treatment.
Conclusions
While 38% (11 of 29) of intensive group patients failed to reach their target BP, our overall findings are consistent with there being no association between BP lowering and change in CBF (or increased clinical AEs) over a 3-month period compared with standard BP lowering. This suggests that intensive BP lowering does not cause cerebral hypoperfusion in patients with severe SVD.
They had no role in the collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. To determine whether a strategy of intensive, versus standard, treatment of BP in hypertensive individuals with cerebral small vessel disease (SVD) and leukoaraiosis is associated with reduced cognitive decline.
PRESERVE: BP treatment in SVD
Secondary
Objective:
1. In a subgroup of the overall RCT to determine whether a strategy of intensive, versus standard, treatment of BP in hypertensive individuals with SVD and leukoaraiosis is associated with brain changes detectable on serial MRI imaging: namely a reduced rate of white matter damage assessed by Diffusion Tensor Imaging, a reduced rate of brain atrophy and an increase in cerebral blood flow (CBF) 2. To compare the sensitivity of diffusion tensor MRI and brain atrophy as surrogate markers of white matter damage for therapeutic trials and their relationship to cognitive decline, compared with the conventional MRI marker of T2 white matter lesion volume 
Background
Cerebral small vessel disease (SVD) accounts for about 20% of all stroke (lacunar stroke) and is now recognised to be the major cause of vascular cognitive impairment and dementia (1).
Therefore, it presents a major public health problem. It arises from disease in the small perforating arteries supplying the white matter and deep gray matter structures. Radiologically one sees a combination of small discrete lacunar infarcts with or without more diffuse ischaemic changes, best seen on T2-weighted Magnetic Resonance Imaging (MRI) as high signal and referred to as leukoaraiosis (or white matter hyperintensities).
In patients with cognitive impairment due to SVD a characteristic picture of "subcortical" cognitive impairment is seen with impairment of executive function and information processing speed being prominent while episodic memory is preserved. that as many as 50% of patients with lacunar stroke have cognitive deficits. (4, 5) Cognitive deficits are much more common in SVD patients with accompanying leukoaraiosis.
Leukoaraiosis in this patient group is related to progressive cognitive impairment and a high risk of developing dementia and disability. (6, 7) The recent prospective LADIS study in 639 subjects showed leukoaraiosis specifically contributed to the deterioration in psychomotor speed and executive function which occurred during follow-up. (7) Despite this association between leukoaraiosis and cognition, the correlation between cognition and MRI T2-lesion volume (leukoaraiosis volume) in patients presenting with clinical SVD is weak. (8, 9) This may be because T2-high signal does not differentiate between areas of increased water content and structural damage.(10) Using Diffusion Tensor Imaging (DTI) it is possible to better image white matter tract structure, and we have shown that DTI parameters correlate highly significantly with cognitive impairment in this group, and to a greater extent than T2-lesion volume. (8, 9, 11) This supports a role for white matter tract damage and subsequent cortical-subcortical disconnection in causing cognitive impairment in these patients. Hypertension is the major risk factor for SVD, being present in up to 80-90% of patients with lacunar stroke and leukoaraiosis. (12) In asymptomatic individuals there is a strong relationship between blood pressure(BP) and leukoaraiosis volume, and treatment of BP reduces leukoaraiosis progression. (13, 14) However, the situation is more complex in patients with symptomatic SVD, particularly in those with accompanying leukoaraiosis. In stroke patients as a whole there is strong evidence that treating BP, even in individuals with BP in the "normal" range, reduces recurrent stroke as well as heart and renal disease.(15) However, it has also been suggested that over-zealous treatment of BP in this group with extensive leukoaraiosis could have deleterious consequences.(16) An important mechanism underlying leukoaraiosis is believed to be hypoperfusion in the internal watershed areas at the distal supply of the perforating arteries. We, and others, have confirmed reduced white matter cerebral blood flow (CBF) in SVD, (17, 18) and impaired cerebral autoregulation has also been reported. There are no randomised controlled trials which have adequately addressed the issue of benefits and risks from different target BP.
We have reviewed the available data (16, 30) CBF in older patients with hypertension without SVD (see above). We will apply this technique to SVD with leukoaraiosis to determine the relationship between BP lowering and CBF.
To investigate these questions we will perform this current clinical trial with nested sub-studies.
Specifically this will include: 1. A randomised controlled trial (RCT) of intensive versus usual blood pressure lowering treatment with cognition as a primary end point.
2. Nested within the RCT in a subgroup of the overall trial population, a sub-study with progression of white matter damage, assessed using DTI, as the primary endpoint. To determine whether a strategy of intensive, versus standard, treatment of BP in hypertensive individuals with SVD and leukoaraiosis is associated with reduced cognitive decline.
Secondary objectives
A. In a subgroup of the overall RCT to determine whether a strategy of intensive, versus standard, treatment of BP in hypertensive individuals with SVD and leukoaraiosis is associated with brain changes detectable on serial MRI imaging:
A reduced rate of white matter damage assessed by Diffusion Tensor Imaging A reduced rate of brain atrophy (global, or grey or white matter)
An increase in CBF B. To compare the sensitivity of diffusion tensor MRI and brain atrophy as surrogate markers of white matter damage for therapeutic trials and their relationship to cognitive decline, compared with the conventional MRI marker of T2 white matter lesion volume.
6 Trial design
Overall design
This is a randomised trial of two treatment strategies (intensive versus standard) for lowering blood pressure in patients with SVD and radiological leukoaraiosis.
Within this overall study there will be two nested sub-studies which some, but not all, patients will also enter:
1. DTI MRI substudy
Perfusion MRI study
Undertaking such a treatment trial double blind would be very difficult and previous trials of BP lowering intensity (e.g. HOT) have not used double blind treatment regimens. To avoid bias in outcome assessment there will be blinded assessment of the following outcomes: Informed consent will be taken by medical staff at SpR level or above or Senior Research nursing staff (Band 6 and above).
Patient will be given up to 7 days to decide whether they wish to take part.
Participant Loss of Capacity
Because cognitive dementia is common among patients with cerebral small vessel disease, it is possible that individual participants may lose capacity to consent over the course of the study. At the point of recruitment, it is specified in the inclusion criteria that all participants must be able to provide consent to join the study. If, during the course of the study, there are any concerns about a participant's capacity to consent (using the Mental Capacity Act (2005) as a guide), a consultee will be approached to provide advice on the participant's continued participation. We will ask the participant to identify a consultee, usually a partner or family member or carer, at the baseline visit
Randomisation procedure
Patients will be randomised to Usual or Intensive blood pressure lowering. Randomisation will be in the ratio 1:1 and performed via an online randomisation system, available 24 hours, based at the Mental Health & Neuroscience Clinical Trials Unit (MH&N CTU) at the Institute of Psychiatry.
Randomisation will be stratified by centre.
Treatment strategies
Patients will be randomised between two treatment strategies: This is a trial comparing two strategies for lowering blood pressure and not of specific blood pressure drugs. We are not ascertaining, verifying or comparing efficacy of medicines, only different BP targets achieved by pharmacological and non-pharmacological means. BP lowering management will be the responsibility of the local PI at each site. Sites will be provided with Both groups will be given home blood pressure monitors and asked to perform daily blood pressure readings for at least three days prior to each pre-arranged telephone follow-up. On each occasion they will take a reading in the seated position always from the same arm (left unless specified).
1.
The intensive BP lowering group will have BP lowering treatment increased at baseline assessment and be reviewed by telephone at two weekly intervals. If average BP at any followup is >125 mmHg treatment will be increased until target systolic BP of <125 mm Hg is achieved (average of 2nd and 3rd of three seated BP readings), or symptoms of hypotension prevent treatment being intensified. If dose of an existing drug is instituted this can be done over the telephone but if a new agent is required the patient will attend for the prescription.
2.
The usual BP lowering group will have treatment unchanged at study entry. They will be contacted for two weekly intervals for the first month and then seen for regular follow-up as outlined blow. At follow-up if average systolic BP is above 140 mmHg treatment will be increased until target systolic BP of <140mmHg or symptoms of hypotension prevent treatment being intensified.
Note: Patients taking part in the perfusion MRI study will not have their treatment altered until they have had their baseline MRI scan.
The NICE/British Hypertension Society guideline based algorithm will act as a guide to treatment but all treatment decisions will be made by the local principal investigator. In both treatment groups treatment will be changed if the patient experiences adverse effects considered by the local PI to be related to the BP lowering treatment.
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Study Assessments
Screening assessments
At a screening assessment potential study participants will be reviewed with the following to ensure they meet the inclusion criteria and do not have exclusion criteria and the researcher will fill in a screening checklist. Assessments will include:
1. Review of medical records and clinical history to confirm clinical diagnosis consistent with cerebral small vessel disease 2. Review of MRI brain imaging to confirm presence of lacunar infarction and confluent leukoaraiosis (>= Fazekas grade 2)-in conjunction with leukoaraiosis grading package 3. Baseline medical examination including BP. Study BP measurements will be taken as the mean of the last two of three reading taken in the sitting position after 5 minutes rest.
Review of current medication including number and doses of antihypertensive agents to
ensure appropriate prior to study entry. 
Baseline assessments
Clinical assessment
Assessment of cognition
The primary outcome will be changes in a composite cognitive score with cognition assessed by a battery of tests known to be sensitive to impairments in attention, information processing and executive function due to subcortical white matter disease (1). This will yield a composite score comprising data from the following tests. Times each test takes are shown in brackets. In addition premorbid intellectual functioning at baseline will be assessed using the National Adult
Reading Test -Restandardised (NART-R) (39) (5 minutes). 
Other asssessments
Summary flow table of study assessments
See Appendix 1 and 2
Laboratory and radiological procedures
Laboratory procedures
Blood will be taken at baseline for both DNA extraction and storage of serum. Genotyping of polymorphisms discovered as part of ongoing genome wide association studies will be performed.
Blood will be taken by venupuncture into tubes for serum and into EDTA tubes for DNA. Serum samples will be centrifuged and serum separated and pipetted into a storage tube and both extracted serum and EDTA will be stored in a freezer at ≤ -70 o C in the local centre until transferred to CUH. Extracted DNA samples may be sent for additional genotyping to other centres in the UK or Europe for specific analyses as part of future collaborative projects.
Radiology or any other procedure(s)
Only patients who have undergone an MRI brain scan prior to screening can be assessed for suitability for the study. It is anticipated that patients will have already had an MRI scan performed for clinical management purposes. Patients who have a MRI scan planned can be screened for eligibility prior to this being performed. All MRI used at screening to confirm eligibility must have been performed within 2 years of randomisation and the patient must have suffered no new stroke with residual disability since the scan was performed.
Only patients within the MRI substudies will have MRI scans as part of the study. All patients recruited to the MRI substudies will be part of the larger RCT. Subjects can be in either or both of the MRI substudies. All of these additional MRI scans will be performed using clinical MRI scanners at field strengths of 1.5 or 3T and do not involve exposure to radiation. MRI does not involve radiation and there will be no contrast administration. 
DTI-MRI sub-study
A standardised MRI protocol will be performed at baseline and after 2 years.
This will include:
high resolution 3D T1-weighted images (for brain volume) ~4.5 minutes T2-weighted gradient echo (GE) images (for identification of microbleeds) ~7 minutes FLAIR (for computation of lesion volume) ~4.5 minutes DTI (for white matter structural analysis). DTI provides quantitative measures (fractional anisotropy and diffusivity (including axial, radial and mean diffusivity) which can be compared both longitudinally and across sites. High angular resolution diffusion-weighted images will be acquired using a pulsed gradient spin echo planar imaging (EPI) sequence in approximately 11 minutes.
Perfusion sub-study
Subjects in this substudy will have the standard MRI protocol above and in addition will have cerebral blood flow (CBF) / perfusion studies CBF MRI will be performed at baseline, 3 months, and at 2 years.
The CBF MRI will take place in two sites (Newcastle and St George's) only. These sites have similar 3 Tesla Phillips MR systems. Randomisation will be stratified by study centre/scanner (St George's v Newcastle) reducing bias.
The arterial spin labelling (ASL) technique we will use has been implemented at Newcastle in studies on hypertensive individuals and identical protocols will be used in each centre. CBF is measured using an ASL sequence with Gradient Echo ( 
Definition of the End of Trial
This is the Last Patient Last Visit (LPLV) (i.e. telephone call, home visit, hospital visit).
Drop outs
If subjects discontinue for any reason, if possible an assessment including cognitive assessment will be performed just prior to study exit
Recording Adverse Events (AEs)
A record of adverse events will be recorded and the relationship to treatment assessed and forwarded to the study co-ordinating centre A record of adverse events will be collected at each follow-up visit.
Specifically we will ask at each visit about
Falls
Dizzyness/postural instability 13 Data management and quality assurance
Confidentiality
All data will be handled in accordance with the Data Protection Act 1998.
The Case Report Forms (CRFs) will not bear the subject's name or other personal identifiable data. The subject's initials, Date of Birth (DOB) and trial Identification Number (ID), will be used for identification.
Data collection tool
All on case report forms, data will be entered legibly in black ink with a ball-point pen. If the Investigator makes an error, it will be crossed through with a single line in such a way to ensure that the original entry can still be read. The correct entry will then be clearly inserted. The amendment will be initialled and dated by the person making the correction immediately.
Overwriting or use of correction fluid will not be permitted. 
DTI-MRI substudy
We will include 180 subjects (90 in each arm) in this substudy; sample sizes are based on FA values from our DTI longitudinal study. With p<0.05, and power of 0.9, and with SD in control group of 6.0 x 10-3 and difference between 2 interventions of 3.1x10-3 we require 80 in each group ie 160 total, which we have increased by 12.5 % ( a figure based on our SCANS prospective MRI study) to 180 to account for attrition.
Perfusion substudy
Global CBF, and white and grey matter CBF will be determined. We will determine whether there are significant differences in change in CBF between the two groups. In our recent COGFAST 
Statistical analysis plan
Primary endpoint analysis
To avoid bias due to multiple testing of the large number of neuropsychological tests a composite executive function score will be calculated by averaging z scores (calculated using the DKEFS normative data) for the Trail Making, Digit Symbol Coding and Verbal Fluency tests. For Trail Making adjusted outcome scores will be the difference between the TMT-B and TMT-A times and the difference between the TMT-B and motor speed. Data will be analysed on an intention to treat basis.
The primary analysis will be change between baseline and year 2.
The primary analysis will be intention to treat after patients excluded after review of the screening scan for not having small vessel disease/lacunar infarction have been excluded A per protocol analysis will also be performed. 
Secondary endpoint analysis
The secondary endpoint analysis will be intention to treat after patients excluded after review of the screening scan for not having small vessel disease/lacunar infarction have been excluded A per protocol analysis will also be performed.
Randomisation
There may be differences between sites in MRI system characteristics and for this reason randomisation to the MRI substudy is stratified by site.
Committees in involved in the trial
1. Trial Management Group (TMG) -This will be responsible for day-to-day management of the trial and will comprise the CI, the trial manager, and study clinical research fellows and neuropsychologist. They will co-ordinate regular teleconferences (eg monthly) with co-ordinating staff from St. George's University of London, University of Cambridge, Oxford University and Newcastle University. The role of the group is to monitor all aspects of the conduct and progress of the trial, ensure that the protocol is adhered to and take appropriate action to safeguard participants and the quality of the trial itself.
Trial Steering Committee (TSC) -This will provides overall supervision of the trial and
ensures that it is being conducted in accordance with the principles of GCP and the relevant regulations.
Independent Data Monitoring Committee (IDMC)
-This will regularly monitor trial progress assess whether there are any safety issues that should be brought to participants' attention or any reasons for the trial not to continue.
Direct access to source data
The Investigator(s)/institution(s) will permit trial-related monitoring, audits, REC review, and regulatory inspection(s), providing direct access to source data/documents. Trial participants are informed of this during the informed consent discussion. Participants will consent to provide access to their medical notes. 
Ethics and regulatory requirements
The Sponsor will ensure that the trial protocol, Patient Information Sheet (PIS), Informed Consent Within 90 days after the end of the trial, the CI and Sponsor will ensure that the main REC are notified that the trial has finished. If the trial is terminated prematurely, those reports will be made within 15 days after the end of the trial.
The CI will supply a summary report of the clinical trial to the main REC within one year after the end of the trial.
Monitoring plan for the trial
The trial will be monitored according to the monitoring plan agreed and written by the Sponsor, based on the internal risk assessment procedure.
Finance and funding
The study is funded by a Stroke Association/British Heart Foundation Programme Grant. 
Insurance and indemnity
Publication policy
Results will be published in peer reviewed journals and presented at conferences. Publications policy will be decided by the steering committee.
Statement of compliance
The trial will be conducted in compliance with the protocol, Sponsor's Standard Operating Procedures (SOPs), GCP and the applicable regulatory requirement(s).
The This study will be conducted in compliance with the protocol approved by the REC and according to GCP standards. No deviation from the protocol will be implemented without the prior review and approval of the Sponsor and REC except where it may be necessary to eliminate an immediate hazard to a research subject. In such case, the deviation will be reported to the Sponsor and REC as soon as possible. 12 2. t-test/Mann Whitney U -Compare Adverse Events "AE between the two groups. 13 14 Further Sub-group Analyses 15 New patient groupings will be generated based those who achieved their bp target at 3 16 months (i.e. <125 systolic vs. >130 systolic as per the study targets). Repeat the above 17 ANOVA analyses with these sub-groups. 18 19 Further Analyses 20 Linear regression Change in bp vs. change in CBF. The Analyses 31 General statistical bookkeeping 32  Check distribution of all variables in main treatment and subgroups. 33  Homogeneity of variance tests between variables after being split into groupings 34 based on treatment / bp. 35  Examinations to make sure the different experimental groups (both treatment arm 36 and achieved bp groupings) are similar, i.e. groupwise testing to examine for any 37 baseline differences in: 38 o Age 39 o Days from stroke to scan 40 o Days between baseline and 3 month scan  Independent t-tests to statistically examine bp change between treatment groups. 56 Testing our main objectives 57  Primary outcome of change in CBF between treatment groups will be tested using an 58 ANOVA which also controls for site.
59
 Secondary outcomes of the different tissue ROI will also be tested between 60 treatment groups in an ANOVA, controlling for site. 61  These tests will be repeated using the different groupings based on patients who 62 <125, standard= >130).
63
 Where appropriate after an ANOVA, post-hoc tests looking at exact means / hazard 64 ratios etc. will be conducted. Levines Test of equal variances will also be used to see 65 that ANOVA assumptions have been met. Analysis will be repeated using non-66 parametric testing when necessary.
67  A regression model will use change in CBF as the DV and baseline / 3 month change 68 in bp as a predictor variable to examine this relationship (while controlling for site).
69
 The distribution of residuals will be inspected for normality following regressions to 70 ensure that regression assumptions have been met. 71  T A E "AE 72 their chance of being related to the study drug) will be compared between groups by 73 independent t-tests / Mann Whittney U as appropriate.
